The Goodwin Life Sciences and Global M&A teams advised Arthrosi Therapeutics, Inc. (Arthrosi) on the signing of a definitive agreement for its acquisition by Swedish Orphan Biovitrum AB (Sobi) for an upfront consideration of $950 million, together with up to $550 million in clinical, regulatory and sales milestones. The transaction is subject to the satisfaction of customary closing conditions and is expected to close in H1 2026.
Arthrosi, headquartered in San Diego, CA, is a late-stage biotechnology company focused on developing pozdeutinurad, a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate levels, flares and tophi in patients with progressive gout.
Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's shares are listed on Nasdaq Stockholm (STO:SOBI).
The Goodwin team was led by Wendy Pan and Shoaib Ghias, and included Amine Assouad, Yifeng Yuan, Yichen Xu, Chukwubuikem Nnebe, Seva Castleberry, David R. Chen, Christopher Zhong, Jo-an Chen, Longfei Fang, Susan Lee, Krupa Zachariah, Jacqueline Klosek, Jacob Lee, April Sun, Nina Ngo, Laura Conway, Malhar Naik, Eric Graffeo, Justin C. Pierce, Gozde Guckaya, Carrie Clowney, Daniel Karelitz, Gregg Coughlin, Arman Oruc, Brady Cummins, Kevin Walsh, Arom Yun, Robert D. Carroll, Heath R. Ingram, Kevin Guan, and Vicky Ling.
For more information on the deal, please read the press release.